John Agwunobi is the former chief executive officer and chairman of the board of Herbalife Nutrition, a premier global nutrition company that serves customers in 94 countries. Agwunobi joined Herbalife Nutrition in 2016 as its chief health and nutrition officer. In March 2020 he was appointed chief executive officer, where he was responsible for overseeing all aspects of the company’s growth, with a keen focus on initiatives that can positively impact issues affecting global society, including overweight and obesity, healthy aging, and a business opportunity.

During his tenure, Agwunobi worked closely with Herbalife Nutrition independent distributors and customers, to ensure continuous innovation in the areas of product development, technology, marketing and distributor sales. He also led the Herbalife Nutrition Institute, the Herbalife Nutrition Advisory Board, and the Herbalife Dietetic Advisory Board and worked with the company’s Ph.D.s and scientists to integrate nutrition science into Herbalife Nutrition products.

Prior to joining Herbalife, Agwunobi served as senior vice president and president of health and wellness for the world’s largest retailer, Walmart, where he led a team of over 65,000 and grew the business from $25 billion to over $30 billion. In the public sector, Agwunobi served as Florida’s secretary of health and later as an admiral in the U.S. Public Health Services Commissioned Corps and the assistant secretary of health for the U.S. Department of Health and Human Services. In these roles, he was responsible for disease prevention and health promotion. He oversaw the Centers for Disease Control, the National Institutes of Health, the Food and Drug Administration, the office of the U.S. Surgeon General, and numerous other public health offices and programs.

Agwunobi has a broad educational background that includes a master's degree in public health from Johns Hopkins University and a master's degree in business administration from Georgetown University. He completed his pediatric residency at Howard University and is currently a licensed physician in Florida. In addition to the Board of Directors for bluebird bio, Agwunobi also serves on the Board of the Ensign Group, Inc. and the Board of the U.S. African Development Foundation.

Mike is President and Chief Executive Officer of Sionna. He is a respected biotech leader with over 20 years of biopharma experience across global organizations. Most recently he served as Chief Operating Officer at Sage Therapeutics leading all the business functions (commercial, medical affairs, government affairs, business development, technical operations, strategy and program management) and G&A functions. During his four years with Sage, he helped lead the growth of the organization through multiple capital raises, the launch of the company’s first product, and execution of a transformational, multi-billion-dollar collaboration.

Prior to Sage, he had a 14-year tenure at Biogen in various business and commercial roles. His most recent role at Biogen was as Senior Vice President, U.S. Commercial, where he was the general manager of the multi-billion-dollar MS, hemophilia, and SMA franchises. Prior to Biogen, Mike worked at Bain & Company as a consultant specializing in healthcare. Mike earned his MBA from the Darden Graduate School of Business Administration at the University of Virginia and a B.A. from College of the Holy Cross.

Charlotte Jones-Burton, MD, MS most recently served as Senior Vice President, Product Development and Strategy at Chinook Therapeutics, a clinical-stage biotechnology company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases. With more than 20 years of experience as a clinical development leader, internal medicine and nephrology physician and academician, Dr. Jones-Burton is dedicated to creating healthier communities through drug development, patient advocacy and people engagement.

Dr. Jones-Burton earned a medical degree and Master of Science degree in Epidemiology and Preventive Medicine, with a concentration in Clinical Research, from the University of Maryland School of Medicine. Charlotte’s postgraduate training included an internal medicine residency and a nephrology fellowship at the University of Maryland Medical Systems. Immediately prior to her current role at Chinook Therapeutics she was VP, Global Clinical Development Head, Nephrology at Otsuka Pharmaceutical Development & Commercialization, Inc.

Dr. Jones-Burton is active in numerous professional associations and organizations and founded Women of Color in Pharma (WOCIP), a non-profit professional society focused on transforming the pharmaceutical landscape with women of color. In 2021, she was recognized as one of the industry’s top 100 inspiring people by PharmaVoice and awarded the 1st ever Global Icon Award by WOCIP.

Dr. Leiderman is the Chief Financial Officer and Corporate Development Officer at Dewpoint Therapeutics, where she brings more than 15 years of expertise in business development, strategy, and finance in the life sciences industry to her role. Prior to joining Dewpoint, she served as Chief Financial Officer & Chief Business Officer at Atsena Therapeutic, a clinical-stage gene therapy company developing novel treatments for inherited forms of blindness; and Chief Financial Officer and Head of Corporate Development at Decibel Therapeutics, a clinical-stage biotechnology company developing novel gene therapeutics for restoration of hearing loss and balance disorders. Dr. Leiderman also served as Chief Business Officer for Complexa, Inc., a clinical stage biopharmaceutical company focused on life-threatening fibrosis and inflammatory diseases and Senior Vice President, Head of Corporate Development at Fortress Biotech, where she was responsible for key business growth initiatives, including business development, strategy, financial analysis and capital raising.

Dr. Leiderman spent 10 years as a healthcare investment banker advising global corporate clients and their boards. Her significant transaction experience includes mergers and acquisitions, other strategic transactions, initial public offerings, and other equity and debt financings in the healthcare sector. She began her career in medical affairs at AstraZeneca in their neuroscience division.

Dr. Leiderman earned an M.D. from the American Medical Program Tel Aviv University, an MBA from The Wharton School at the University of Pennsylvania and a B.A. from The University of Pennsylvania.

Najoh Tita-Reid was appointed Chief Brand and Experience Officer, Mars Petcare in November 2023 to lead brand, experience, digitalization and technology to drive business transformation.

Najoh previously served Global Chief Marketing Officer for Logitech, a global manufacturer of computer peripherals, software, and services with headquarters in Switzerland and California, where she led the global marketing function and creation of the company’s digital-first, and data-driven consumer and customer omnichannel experience strategy. A multi-faceted executive with global marketing expertise, she has a record of strategic and operational ingenuity and transformation across complex organizations and a breadth of experience across the US and Europe.

Prior to her role at Logitech, Ms. Tita-Reid was Global Chief Marketing Officer and Executive Board Member for Hero-AG, a family-run healthy food company and held leadership positions at Bayer PLC, where she served as Vice President-Country Division Head for Consumer Care in the UK in Ireland and led the turnaround of the consumer care business; and Merck & Co, Inc where she served as General Manager for Western Europe.

Ms. Tita-Reid spent 19 years at Procter & Gamble where she managed a number of consumer brands in the baby and feminine care categories. At P&G, Ms. Tita-Reid spearheaded multi-cultural marketing strategy across 15 billion-dollar brands and led the multi-brand business unit for Hispanic and African American consumers. During her tenure, Ms. Tita-Reid trained and developed the P&G marketing function on ethnic marketing, and created breakthrough marketing strategies, including “My Black is Beautiful,” which stands as a template for multi-cultural campaigns across industry today.

Ms. Tita-Reid graduated with a Bachelor of Arts from Spelman College and holds an MBA from Fuqua School of Business at Duke University.